Loading...

Intellectia LogoIntellectia
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. NVNO
NVNO logo

NVNO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • AI Stock Picker
  • Swing Trading
  • SwingMax Portfolio
  • QuantAI Alpha Pick
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • Financial AI Agent
  • AI Screener
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
12.700
Open
11.000
VWAP
12.13
Vol
15.96K
Mkt Cap
7.06M
Low
11.000
Amount
193.61K
EV/EBITDA(TTM)
--
Total Shares
654.29K
EV
-23.88M
EV/OCF(TTM)
--
P/S(TTM)
--
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Show More

Events Timeline

(ET)
2026-01-16
20:00:00
enVVeno Medical Trading Halted, News Pending
select
2025-11-13 (ET)
2025-11-13
17:03:49
enVVeno Medical faces setback as FDA issues negative ruling on VenoValve
select
2025-10-31 (ET)
2025-10-31
08:11:27
enVVeno Medical Announces Q3 Earnings Per Share of 23 Cents, Compared to 35 Cents Last Year
select
2025-09-15 (ET)
2025-09-15
08:48:55
enVVeno Medical Plans to Appeal CDRH's Non-Approval Decision
select
2025-08-20 (ET)
2025-08-20
07:22:35
enVVeno Medical Gets FDA's Not-Approvable Letter for VenoValve
select
2025-08-06 (ET)
2025-08-06
08:41:41
enVVeno Medical announces findings from health economic study of VenoValve
select
2025-08-04 (ET)
2025-08-04
09:13:08
enVVeno participates in 'What This Means' segment on Trump's CVI diagnosis
select
2025-08-01 (ET)
2025-08-01
08:13:11
enVVeno Medical expects capital to fund company through 3Q26
select

News

seekingalpha
8.5
01-15seekingalpha
enVVeno Medical Approves 1-for-35 Reverse Stock Split, Reducing Shares to 655K
  • Reverse Stock Split Decision: enVVeno Medical's board approved a 1-for-35 reverse stock split effective January 20, 2026, reducing outstanding shares from approximately 22.9 million to about 655,000, aiming to enhance share price and attract investor interest.
  • Exchange Arrangement: Post-split, the company's common stock will resume trading on the Nasdaq Capital Market under the existing ticker symbol 'NVNO', indicating a strategic move to improve market perception and liquidity.
  • Market Reaction: Following the reverse split announcement, enVVeno Medical's stock price fell 19.69% in premarket trading to $0.2761, reflecting negative market sentiment that could impact investor confidence.
  • Shareholder Impact: The reverse split will consolidate every 35 shares into one, which may reduce the number of shares held by shareholders in the short term, but the company aims to improve long-term investment appeal through a higher share price.
Benzinga
4.5
2025-11-14Benzinga
Gold Drops More Than 2%; Cidara Therapeutics Stock Soars
  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones falling 0.44%, while the NASDAQ and S&P 500 rose by 0.59% and 0.27%, respectively. Utilities shares increased slightly, but communication services stocks dropped by 1%.

  • Notable Company Performances: Spire Inc's shares fell over 2% after reporting larger-than-expected quarterly losses, while Cidara Therapeutics saw a 105% surge in shares following Merck's acquisition announcement.

  • Commodities Update: Oil prices rose by 1.9% to $59.81, while gold and silver prices fell by 2.2% and 5%, respectively. Copper also saw a decline of 1.1%.

  • Global Market Trends: European shares declined, with the STOXX 600 down 1.54%, and Asian markets mostly closed lower, highlighted by Japan's Nikkei 225 dropping 1.77%.

Benzinga
4.5
2025-11-14Benzinga
Nasdaq Falls by More Than 300 Points; Applied Materials Reports Positive Q4 Earnings
  • Market Performance: U.S. stocks opened lower, with the Dow down 1.21%, Nasdaq falling 1.51%, and S&P 500 decreasing by 1.17%. European and Asian markets also experienced declines.

  • Sector Movements: Real estate shares rose by 0.3%, while information technology stocks fell by 1.2%. Notable stock movements included Cidara Therapeutics surging 106% after a Merck acquisition announcement.

  • Company Earnings: Applied Materials reported better-than-expected fourth-quarter results and projected first-quarter revenue above estimates, while several companies, including Gauzy Ltd and enVVeno Medical Corp, faced significant stock declines.

  • Commodity Updates: Oil prices increased by 1.9% to $59.82, while gold and silver prices fell by 3.4% and 5%, respectively. Economic data on oil rig counts is expected to be released today.

Benzinga
2.0
2025-11-14Benzinga
RLX Technology Shares Rise 6%; Check Out 20 Stocks Making Moves in Premarket Trading
  • RLX Technology Inc Performance: RLX Technology's shares rose 6% to $2.47 in pre-market trading after reporting third-quarter earnings of 3 cents per share and $158.6 million in sales.

  • Notable Gainers: Cidara Therapeutics surged 92% to $203.50 following a significant ownership disclosure, while other companies like Binah Capital Group and Expion360 also saw substantial pre-market gains.

  • Significant Losers: TSS Inc experienced a 40.2% drop to $9.10 after reporting a year-over-year decline in financial results, with enVVeno Medical Corp and Nuvve Holding Corp also facing significant losses.

  • Market Overview: The pre-market trading session showed a mix of gains and losses among various stocks, reflecting varied financial performances and investor reactions to earnings reports.

Benzinga
4.5
2025-08-20Benzinga
Nasdaq Declines 1%; Lowe's Reports Positive Earnings
  • U.S. Stock Market Performance: U.S. stocks declined mid-session, with the Nasdaq Composite dropping over 200 points and the S&P 500 and Dow also experiencing losses.

  • Lowe's Earnings Report: Lowe's Companies reported better-than-expected second-quarter earnings, with adjusted EPS rising to $4.33 and quarterly sales reaching $23.96 billion, prompting an update in fiscal guidance.

  • Equities Movement: NovaBay Pharmaceuticals saw a significant stock increase of 68% after a securities purchase agreement, while enVVeno Medical Corporation shares plummeted 72% following FDA news.

  • Global Market Trends: European shares showed mixed results, Asian markets closed mixed with Japan's Nikkei falling, and U.S. mortgage applications decreased by 1.4% from the previous week.

TipRanks
4.5
2025-08-20TipRanks
Wednesday's Major Stock Market Highlights: Morning News Summary!
  • Stock Market Highlights: The article discusses the major stock market stories from Wednesday, emphasizing significant news that investors should pay attention to.

  • TipRanks Coverage: TipRanks has curated a selection of the most relevant and impactful stock market news for readers.

  • Market Trends: The content suggests that there are various trends and developments in the stock market worth exploring further.

  • Disclaimer: A disclaimer is included, indicating the information is based on data available up to October 2023.

Valuation Metrics

The current forward P/E ratio for enVVeno Medical Corp (NVNO.O) is -0.32, compared to its 5-year average forward P/E of -3.33. For a more detailed relative valuation and DCF analysis to assess enVVeno Medical Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.33
Current PE
-0.32
Overvalued PE
-1.65
Undervalued PE
-5.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
44.27
Current PS
4.72
Overvalued PS
106.84
Undervalued PS
-18.29

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

low float. price between 2 and 20.
Intellectia · 908 candidates
Price: $2.00 - $20.00Floating Shares: <= 20,000,000
Ticker
Name
Market Cap$
top bottom
ELPW logo
ELPW
eLong Power Holding Ltd
58.63M
VIVS logo
VIVS
VivoSim Labs Inc
7.62M
ASBP logo
ASBP
Aspire Biopharma Holdings Inc
7.37M
BUUU logo
BUUU
BUUU Group Ltd
191.60M
MOGU logo
MOGU
Mogu Inc
19.37M
CNCK logo
CNCK
Coincheck Group NV
388.75M
what stocks have a small float?
Intellectia · 2475 candidates
List Exchange: XNYS, XNAS, XASEFloating Shares: <= 50,000,000
Ticker
Name
Market Cap$
top bottom
STRC logo
STRC
Strategy Inc
42.03B
DIT logo
DIT
Amcon Distributing Co
71.58M
SLGL logo
SLGL
Sol Gel Technologies Ltd
172.80M
SEB logo
SEB
Seaboard Corp
4.77B
IOR logo
IOR
Income Opportunity Realty Investors Inc
73.19M
LYRA logo
LYRA
Lyra Therapeutics Inc
3.59M
what stock currently have a small float.
Intellectia · 2908 candidates
Floating Shares: <= 50,000,000
Ticker
Name
Market Cap$
top bottom
STRC logo
STRC
Strategy Inc
42.03B
CAPS logo
CAPS
Capstone Holding Corp
5.24M
DIT logo
DIT
Amcon Distributing Co
71.58M
BH.A logo
BH.A
Biglari Holdings Inc
1.23B
SLGL logo
SLGL
Sol Gel Technologies Ltd
172.80M
SEB logo
SEB
Seaboard Corp
4.77B

Whales Holding NVNO

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is enVVeno Medical Corp (NVNO) stock price today?

The current price of NVNO is 12.7 USD — it has increased 17.76

What is enVVeno Medical Corp (NVNO)'s business?

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

What is the price predicton of NVNO Stock?

Wall Street analysts forecast NVNO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVNO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is enVVeno Medical Corp (NVNO)'s revenue for the last quarter?

enVVeno Medical Corp revenue for the last quarter amounts to 0.00 USD, decreased

What is enVVeno Medical Corp (NVNO)'s earnings per share (EPS) for the last quarter?

enVVeno Medical Corp. EPS for the last quarter amounts to -7.88 USD, decreased -35.88

How many employees does enVVeno Medical Corp (NVNO). have?

enVVeno Medical Corp (NVNO) has 37 emplpoyees as of March 05 2026.

What is enVVeno Medical Corp (NVNO) market cap?

Today NVNO has the market capitalization of 7.06M USD.